Munc13-4 mediates tumor immune evasion by regulating the sorting and secretion of PD-L1 via exosomes

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Tumor-derived exosomes carrying programmed death-ligand 1 (PD-L1) suppress anti-tumor immune responses by engaging programmed cell death protein 1 (PD-1) on T cells.
• The precise mechanisms regulating the sorting and secretion of exosomal PD-L1 are not fully understood.

Purpose of the Study:

• To identify key regulators of exosomal PD-L1 sorting and secretion.
• To explore the therapeutic potential of targeting the identified regulatory pathway in breast cancer.

Main Methods:

• Investigated the role of Munc13-4 in exosomal PD-L1 regulation using genetic deletion models in breast tumors.
• Utilized cryogenic electron microscopy (cryo-EM) to analyze the Munc13-4-Rab27a complex structure.
• Examined the formation of a ternary complex involving Munc13-4, PD-L1, and hepatocyte growth factor-regulated tyrosine kinase substrate (HRS).
• Assessed the impact of a peptide designed to disrupt Munc13-4-PD-L1 interaction on tumor immunity and growth.

Main Results:

• Munc13-4 was identified as a crucial regulator of exosomal PD-L1 sorting and secretion.
• Deletion of Munc13-4 in breast tumors enhanced T cell-mediated anti-tumor immunity and suppressed tumor growth.
• Munc13-4 facilitates PD-L1 sorting via a complex involving HRS, Rab27, and SNAREs, influenced by interferon gamma (IFNγ) signaling.
• Structural analysis provided insights into exosome secretion mechanisms.
• A peptide disrupting the Munc13-4-PD-L1 interaction effectively impeded PD-L1 sorting, boosted anti-tumor immunity, and reduced tumor growth.

Conclusions:

• Munc13-4 plays a critical role in the immunosuppressive function of tumor-derived exosomes by regulating PD-L1 secretion.
• Targeting the Munc13-4-PD-L1 interaction presents a promising therapeutic strategy to enhance anti-tumor immunity and improve the efficacy of immune checkpoint inhibitors.